

Opioid Reversal Medication Medication Reimbursement for Uninsured Clients

April 2022



Background

- Substitute Senate House Bill 5195, Section 5 (2) instructs the **Health Care Authority (HCA)** to reimburse hospitals, behavioral health agencies, or pharmacies for dispensing or distributing opioid reversal medication to clients who are not enrolled in a Medicaid Managed Care Plan and do not have any other available insurance coverage.
- SSB 5195, Section 3 Instructs **Hospitals** to provide opioid reversal medication to any person who presents to an emergency department with symptoms of opioid overdose, opioid use disorder, or other adverse event related to opioid use, unless the health care provider deems distribution to not be clinically appropriate.



Background

SSB 5195, Section 4 Instructs all licensed or certified behavioral health agencies that provide treatment must inform a client about opioid reversal medication, ask if the client has opioid reversal medication, and if the client doesn't possess medication the provider must prescribe opioid reversal medication.



What providers need to know

- Eligible providers, hospitals, pharmacies, and BHAs can seek reimbursement from HCA for opioid reversal medication that they dispense to uninsured patients beginning August 22, 2022.
- Reimbursement Facts:
 - ▶ Providers who have records of qualifying distributions can ask for retroactive reimbursement from January 1, 2022.
 - Providers must have either a ProviderOne number or a Statewide vendor (SWV) number. Providers can apply for a SWV <u>here</u>.
 - ➤ Providers will be reimbursed for National Drug Codes related to naloxone products.
 - Reimbursement will be calculated using HCA's billing guide.



What providers need to know

- Provider Contractual Obligations:
 - Providers will be required to sign a contract in order to receive reimbursement. One contract per year per provider will be required. The contract requires providers:
 - > Attest that the provider verified the client has no insurance;
 - ➤ Attest that the client presents with opiate overdose, opioid use disorder, or other adverse event related to opioid use, consistent with RCW 70.41.485(1) and RCW 71.24.594(1)
 - > Contracts will be emailed to providers after they file their first reimbursement request
 - > All contracts must be fully executed prior HCA issuing payment




What providers need to know

- ▶ How to request reimbursement.
 - ► Complete the Uninsured Naloxone Reimbursement form located here.
 - ► Submit a completed form to <u>HCANaloxoneReimbursement@hca.wa.gov</u>
 - ► Providers are encouraged to submit multiple encounters on each form, but requests **should not exceed 4 per month for any provider**.



Overview of the reimbursement process





How to fill out the spreadsheet

Provide	er Name:			
Contact	Name:			
Contact	t Email:			
Contact	Phone Numb	er:		
Provide	rOne or State	wide Vend	orNumber:	
Reimbu	ırsement Time	Period:		

	Dispense	Patient	National	Number	Cost to
Line #	Date	ID	Drug Code	of Units	Facility
1					
2					
3					
4					
5					
6					
7					
8					
9					
10					
11					
12					
13					
14					
15					
16					
17					
18					
19					
20					

rovider Name:
ontact Name:
ontact Email:
ontact Phone Number:
roviderOne or Statewide VendorNumber:
eimhursement Time Period

- Provider name and P1 # or SWV # should match
- Contact name & email- a person that HCA can work with to complete the reimbursement process
- Reimbursement Time Period: Month and Year or dates if the facility/provider is filing more than one form for each month.



How to fill out the spreadsheet

	Line#	Dispense Date	Patient ID	National Drug Code	Number of Units	1	
	1						
)	2						
	3						
	4						
	5						
ļ	6						
,	7						

- Patient ID- Internal number the provider/facility uses to identify the patient. It should be a record that the provider/facility could access in the event HCA needs additional information.
- National Drug Code- indicates the type of medication dispensed.
- Cost to facility- HCA will reimburse using the rates established in its published billing guide. This information will be utilized in the evaluation of those rates and the uninsured reimbursement program.





Questions?

More information:
https://www.hca.wa.gov/about-hca/behavioral-health-recovery/distributing-opioid-overdose-reversal-medications-2ssb-5195

Email: HCANaloxoneReimbursement@hca.wa.go v

Becky Carrell, Deputy Division Director-Medicaid Programs rebecca.carrell@hca.wa.gov 360-972-0347

